Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs Hims and Hers Health Inc — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $32.8 (market cap $1.93B), while Hims and Hers Health Inc trades at $28.38 (market cap $6.89B). The key difference: Hims and Hers Health Inc is far larger — about 3.6× Invesco DB Commodity Index Tracking Fund's market cap, and Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Commodity Index Tracking Fund for 61 Days and Hims and Hers Health Inc for 21 Days on average.
| DBC | HIMS | |
|---|---|---|
Market Cap | $1.93B | $6.89B |
Volume | 569,977 | 5,446,628 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $33.68 | $62.76 |
52-Week Low | $22.07 | $14.52 |
Typical Hold Time | 61 Days | 21 Days |
Enterprise Value | — | $7.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC trades at $32.51, down 0.55% on the day, with a bullish technical signal from moving averages. The company reported $82.59M in revenue and $22.38M net income for 2024, showing improved profitability from 2023's loss. Cash flow from operations was strong at $431.54M, contributing to a healthy balance sheet with $1.28B in shareholder equity and minimal debt.
The outlook appears favorable with positive earnings momentum and robust operational cash flow. Key risks include revenue volatility, as seen in historical fluctuations, and dependence on commodity market conditions. Analyst sentiment is constructive given the bullish technical indicators and improved financial performance.
Hims & Hers Health trades at $29.54, up 0.24% on the day, with a bullish technical signal from moving averages but mixed earnings performance. Revenue grew to $2.35 billion in 2025, yet the company posted a net loss of $142 million in 2026, reflecting profitability challenges. High valuation ratios like a P/E of 57.14 and negative ROE of -32.03% indicate premium pricing despite weak earnings. Recent news highlights multiple securities class action lawsuits filed in October 2026, creating legal overhangs.
The stock faces headwinds from profitability struggles and legal risks, but analyst consensus remains a Buy with a $32.17 price target, suggesting modest upside. Investment appeal hinges on resolving operational inefficiencies and legal issues to align valuation with fundamentals, while current sentiment is cautious due to recent earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
